299 related articles for article (PubMed ID: 28935493)
21. Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing.
Kohsaka S; Petronczki M; Solca F; Maemondo M
Future Oncol; 2019 Feb; 15(6):637-652. PubMed ID: 30404555
[TBL] [Abstract][Full Text] [Related]
22.
Sukari A; Nagasaka M; Wakeling E
J Natl Compr Canc Netw; 2017 Oct; 15(10):1188-1192. PubMed ID: 28982744
[TBL] [Abstract][Full Text] [Related]
23. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
Li Y; Zhang FS; Guo L; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
[No Abstract] [Full Text] [Related]
24. EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience.
Ianza A; Di Chicco A; Biagi C; Giudici F; Dicorato A; Guglielmi A; Variola F; Tomasi S; Roviello G; Generali D; Zanconati F
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2301-2307. PubMed ID: 34003366
[TBL] [Abstract][Full Text] [Related]
25. Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients.
Tran LS; Pham HT; Tran VU; Tran TT; Dang AH; Le DT; Nguyen SL; Nguyen NV; Nguyen TV; Vo BT; Dao HT; Nguyen NH; Tran TH; Nguyen CV; Pham PC; Dang-Mai AT; Dinh-Nguyen TK; Phan VH; Do TT; Truong Dinh K; Do HN; Phan MD; Giang H; Nguyen HN
PLoS One; 2019; 14(12):e0226193. PubMed ID: 31841547
[TBL] [Abstract][Full Text] [Related]
26. EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC).
Reynolds JP; Tubbs RR; Minca EC; MacNamara S; Almeida FA; Ma PC; Pennell NA; Cicenia JC
Lung Cancer; 2014 Nov; 86(2):158-63. PubMed ID: 25263855
[TBL] [Abstract][Full Text] [Related]
27. Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer.
Kasahara N; Kenmotsu H; Serizawa M; Umehara R; Ono A; Hisamatsu Y; Wakuda K; Omori S; Nakashima K; Taira T; Naito T; Murakami H; Koh Y; Mori K; Endo M; Nakajima T; Yamada M; Kusuhara M; Takahashi T
Lung Cancer; 2017 Apr; 106():138-144. PubMed ID: 28285688
[TBL] [Abstract][Full Text] [Related]
28. Clinical and Cost Implications of Universal Versus Locally Advanced-Stage and Advanced-Stage-Only Molecular Testing for Epidermal Growth Factor Receptor Mutations and Anaplastic Lymphoma Kinase Rearrangements in Non-Small Cell Lung Carcinoma: A Tertiary Academic Institution Experience.
Sauter JL; Butnor KJ
Arch Pathol Lab Med; 2016 Apr; 140(4):358-61. PubMed ID: 27028394
[TBL] [Abstract][Full Text] [Related]
29. Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma.
Rachiglio AM; Esposito Abate R; Sacco A; Pasquale R; Fenizia F; Lambiase M; Morabito A; Montanino A; Rocco G; Romano C; Nappi A; Iaffaioli RV; Tatangelo F; Botti G; Ciardiello F; Maiello MR; De Luca A; Normanno N
Oncotarget; 2016 Oct; 7(41):66595-66605. PubMed ID: 27448974
[TBL] [Abstract][Full Text] [Related]
30. Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer.
Iwama E; Nakanishi Y; Okamoto I
Expert Rev Anticancer Ther; 2018 Mar; 18(3):267-276. PubMed ID: 29363369
[TBL] [Abstract][Full Text] [Related]
31. Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS.
Arriola E; Paredes-Lario A; García-Gomez R; Diz-Tain P; Constenla M; García-Girón C; Márquez G; Reck M; López-Vivanco G
Clin Transl Oncol; 2018 Oct; 20(10):1261-1267. PubMed ID: 29623586
[TBL] [Abstract][Full Text] [Related]
32. Rapid and reliable testing for clinically actionable EGFR mutations in non-small cell lung cancer using the Idylla
Michaelidou K; Karniadakis I; Pantelaion V; Koutoulaki C; Boukla E; Folinas K; Dimaras P; Papadaki MA; Koutsopoulos AV; Mavroudis D; Vourlakou C; Mavridis K; Agelaki S
Expert Rev Mol Diagn; 2024; 24(1-2):89-98. PubMed ID: 38193169
[TBL] [Abstract][Full Text] [Related]
33. Liquid biopsy for detection of EGFR T790M mutation in nonsmall cell lung cancer: An experience of proficiency testing in Taiwan.
Ho HL; Huang CC; Ku WH; Ho CL; Lin CH; Yu SL; Chou TY
J Chin Med Assoc; 2019 Jun; 82(6):473-476. PubMed ID: 30932938
[TBL] [Abstract][Full Text] [Related]
34. EGFR mutations in lung cancer: from tissue testing to liquid biopsy.
Fenizia F; De Luca A; Pasquale R; Sacco A; Forgione L; Lambiase M; Iannaccone A; Chicchinelli N; Franco R; Rossi A; Morabito A; Rocco G; Piccirillo MC; Normanno N
Future Oncol; 2015; 11(11):1611-23. PubMed ID: 26043215
[TBL] [Abstract][Full Text] [Related]
35. Critical Assessment in Routine Clinical Practice of Liquid Biopsy for EGFR Status Testing in Non-Small-Cell Lung Cancer: A Single-Laboratory Experience (LPCE, Nice, France).
Heeke S; Benzaquen J; Hofman V; Ilié M; Allegra M; Long-Mira E; Lassalle S; Tanga V; Salacroup C; Bonnetaud C; Fayada J; Gazoppi L; Ribeyre L; Castelnau O; Garnier G; Cattet F; Nanni I; de Fraipont F; Cohen C; Berthet JP; Leroy S; Poudenx M; Marquette CH; Denis MG; Barlesi F; Hofman P
Clin Lung Cancer; 2020 Jan; 21(1):56-65.e8. PubMed ID: 31519454
[TBL] [Abstract][Full Text] [Related]
36. The liquid biopsy: a tool for a combined diagnostic and theranostic approach for care of a patient with late-stage lung carcinoma presenting with bilateral ocular metastases.
Bouhlel L; Hofman V; Maschi C; Ilié M; Allégra M; Marquette CH; Audigier-Valette C; Thariat J; Hofman P
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1087-1092. PubMed ID: 29069959
[TBL] [Abstract][Full Text] [Related]
37. A novel, rapid point-of-care test for lung cancer patients to detect epidermal growth factor receptor gene mutations by using real-time droplet-PCR and fresh liquid cytology specimens.
Asaka S; Yoshizawa A; Matsuda K; Yamaguchi A; Yamamoto H; Shiina T; Nakata R; Ogawa K; Zhang M; Honda T
Oncol Rep; 2017 Feb; 37(2):1020-1026. PubMed ID: 27922678
[TBL] [Abstract][Full Text] [Related]
38. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T
BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131
[TBL] [Abstract][Full Text] [Related]
39. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor T790M testing in progressed lung cancer: A review of sensitive methods for analysis of tissue and liquid biopsy samples.
Chougule A; Basak S
Indian J Cancer; 2017 Dec; 54(Supplement):S45-S54. PubMed ID: 29292708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]